Once-Weekly Semaglutide in Adults with Overweight or Obesity - Wilding, John P.H; Batterham, Rachel L; Calanna, Salvatore; Davies, Melanie; Van Gaal, Luc F; Lingvay, Ildiko; McGowan, Barbara M; Rosenstock, Julio; Tran, Marie T.D; Wadden, Thomas A; Wharton, Sean; Yokote, Koutaro; et al. (The New England journal of medicine, 2021)
Keywords: Adult; Adverse events; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - adverse effects; Antidiabetics; Body composition; Body Composition - drug effects; Body Mass Index; Body weight; Body weight loss; Cardiovascular disease; Cholelithiasis - chemically induced; Clinical trials; Coronaviruses; COVID-19; Diabetes; Diabetes mellitus; Diarrhea; Diarrhea - chemically induced; Diet; Dosage; Double-Blind Method; Female; Gastrointestinal surgery; Glucagon-Like Peptide 1 - agonists; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Healthy Lifestyle; Humans; Hypertension; Injections, Subcutaneous; Intervention; Life Sciences; Lifestyles; Lipids - blood; Male; Middle Aged; Nausea; Nausea - chemically induced; Obesity; Obesity - complications; Obesity - drug therapy; Overweight; Pancreatitis; Placebos; Prediabetic State - complications; Public health; Risk factors; Weight control; Weight Loss - drug effects